GlassScriptPhysician profile
Douglas A Katsev
NPI 1801906722
$458,949.83
in general payments reported to CMS, 2019-2025
49 companies · $85K in 2025
The $85K reported for 2025 was more than what 99% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $190K · 2020: $33K · 2021: $39K · 2022: $22K · 2023: $28K · 2024: $61K · 2025: $85K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $60K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $53K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Food and Beverage: $22K · Travel and Lodging: $15K · Education: $9.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $60,107.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $52,950.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,400.00 |
| Food and Beverage | $21,965.51 |
| Travel and Lodging | $14,776.90 |
| Education | $9.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $124,947.14 | 2022-2025 | Miebo, Xiidra, Envista Mx60 Iol |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $97,514.02 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $46,014.84 | 2019-2022 | |
| Alcon Vision LLC | $45,845.48 | 2019-2025 | Tryptyr, Hydrus Microstent, Clareon |
| Sun Pharmaceutical Industries INC. | $30,954.16 | 2019-2025 | Cequa |
| Shire North American Group INC | $29,492.87 | 2019 | |
| Omeros Corporation | $24,712.90 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $8,224.13 | 2019-2022 | |
| Eyevance Pharmaceuticals LLC | $8,202.31 | 2019-2022 | |
| Rxsight INC | $4,845.92 | 2020-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Glaukos Corporation | $4,058.27 | 2019-2025 | Kxl System, Photrexa Cross-Linking Kit, Ce-Marked Kxla System |
| Harrow Eye, LLC | $3,951.11 | 2023-2025 | Vevye, Iheezo |
| Abbvie INC. | $3,235.70 | 2022-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $3,176.49 | 2019-2025 | Tecnis Iol, Tecnis Iol, Tecnis Simplicity |
| Biotissue Holdings INC. | $2,688.42 | 2019-2024 |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ivantis, INC | $2,563.47 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $1,735.77 | 2023-2025 | Syfovre |
| Allergan, INC. | $1,661.18 | 2019-2022 | |
| Horizon Therapeutics Plc | $1,550.93 | 2021-2023 | Tepezza |
| Carl Zeiss Meditec, INC. | $1,494.25 | 2019-2022 | |
| Eyepoint US, INC. | $1,408.19 | 2019-2021 | |
| New World Medical,INC. | $1,335.36 | 2019-2025 | Clearpath, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Dompe US, INC. | $1,176.78 | 2019-2025 | Oxervate |
| Sight Sciences, INC. | $1,093.79 | 2019-2024 | Omni Surgical System |
| Tarsus Pharmaceuticals, INC. | $1,028.61 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $969.22 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Tearlab Corp | $840.33 | 2022-2023 | Tearlab Osmolarity System |
| Carl Zeiss Meditec USA, INC. | $733.93 | 2021-2024 | Artevo 800, Callisto Eye, Humphrey Hfa |
| Amgen INC. | $568.70 | 2024-2025 | Tepezza |
| Ocular Therapeutix, INC. | $439.73 | 2020-2025 | Dextenza |
| Regeneron Healthcare Solutions, INC. | $357.85 | 2019-2023 | Eylea Hd, Eylea |
| Optos, INC. | $352.00 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $343.15 | 2024-2025 | Purified Cortrophin Gel |
| Lumenis Be INC | $263.79 | 2023 | M22 |
| Merz Pharmaceuticals, LLC | $187.20 | 2021-2025 | Xeomin |
| Nova Eye, INC. | $169.94 | 2025 | |
| Biogen, INC. | $130.24 | 2023 | |
| Ellexiscience | $104.50 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $98.94 | 2023 | Eylea |
| Aerie Pharmaceuticals, INC. | $92.48 | 2019-2020 | |
| Leica Microsystems INC. | $89.37 | 2025 | |
| Mallinckrodt Hospital Products INC. | $85.71 | 2022-2024 | Acthar |
| Akorn Operating Company LLC | $57.73 | 2021 | |
| Johnson & Johnson Vision Care, INC. | $46.11 | 2022-2025 | |
| Rayner Intraocular Lenses Limited | $39.86 | 2023-2024 | Rayone Spheric, Rayone Emv, Omidria |
| Merz North America, INC. | $31.24 | 2020 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Boston Scientific Corporation | $14.66 | 2024 | |
| Travere Therapeutics, INC. | $1.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Katsev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.